Research programme: thyroid hormone agonists-dyslipidaemia - Karo Pharma

Drug Profile

Research programme: thyroid hormone agonists-dyslipidaemia - Karo Pharma

Alternative Names: KB 3495; KB 5359; STADs; TR STAD

Latest Information Update: 21 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Karo Bio
  • Class
  • Mechanism of Action Thyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lipid metabolism disorders

Most Recent Events

  • 12 Feb 2008 Discontinued - Preclinical for Lipid metabolism disorders in Sweden (unspecified route)
  • 04 Jul 2007 This programme is still in active development
  • 14 Oct 2005 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top